Yazarlar (2) |
![]() Kastamonu Üniversitesi, Türkiye |
![]() Islamic Azad University, Central Tehran Branch, Iran |
Özet |
As proof has recommended a close connection between COVID-19 and neurodegenerative disorders, this article aims to investigate the chloroquine (CLQ) drug as the SARS-CoV-2's primary protease, which can prevent in vitro viral duplication of all diverse experiments to present. CLQ is an anti-viral drug enlarged by Pfizer, which can operate as an orally effective 3C-like protease inhibitor. In this study, CLQ has been assessed for its effectiveness against coronavirus by trapping it within a boron nitride nanocage (B |
Anahtar Kelimeler |
CLQ | COVID-19 | Drug delivery | Y--B4N10 (Y = Al, C, Si) |
Makale Türü | Özgün Makale |
Makale Alt Türü | SCOPUS dergilerinde yayımlanan tam makale |
Dergi Adı | Obm Genetics |
Dergi ISSN | 2577-5790 |
Makale Dili | İngilizce |
Basım Tarihi | 04-2024 |
Cilt No | 8 |
Sayı | 1 |
Doi Numarası | 10.21926/obm.genet.2401214 |